CoChat

Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study

Open access
Kuemmel, Sherko, Tondini, Carlo A., Abraham, Jacinta, Nowecki, Zbigniew, Itrych, Bartosz, Hitre, Erika, Karaszewska, Bogusława, Juárez-Ramiro, Alejandro, Morales-Vásquez, Flavia, Pérez-García, Jose Manuel, Cardona-Huerta, Servando, Monturus, Estefania, Sequi, Marco, Restuccia, Eleonora, Benyunes, Mark, Martín, Miguel · 2021 · Breast Cancer Research and Treatment

Published version of a preprint

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

Purpose: Intravenous trastuzumab, pertuzumab, and docetaxel are first-line standard of care for patients with HER2-positive metastatic breast cancer (mBC). MetaPHER is the first study assessing the safety and tolerability of subcutaneous trastuzumab plus intravenous pertuzumab and chemotherapy in a global patient population with HER2-positive mBC. Methods: In this open-label, single-arm, multicenter, phase 3b study, eligible patients were ≥ 18 years old with histologically/cytologically confirmed previously untreated HER2-positive mBC. All received ≥ 1 subcutaneous trastuzumab 600 mg fixed dose plus intravenous pertuzumab (loading dose: 840 mg/kg; maintenance: 420 mg/kg) and docetaxel (≥ 6 cycles; initial dose 75 mg/m 2 ) every 3 weeks. The primary objective was safety and tolerability; secondary objectives included efficacy. Results: At clinical cutoff, 276 patients had completed the study; median duration of follow-up was 27 months. The most common any-grade adverse events were diarrhea, alopecia, and asthenia; the most common grade ≥ 3 events were neutropenia, febrile neutropenia, and hypertension. There were no cardiac deaths and mean left ventricular ejection fraction was stable over time. Median investigator-assessed progression-free survival was 18.7 months; objective response rate was 75.6%. Conclusions: Safety and efficacy with subcutaneous trastuzumab plus intravenous pertuzumab and docetaxel in mBC are consistent with historical evidence of intravenous trastuzumab with this combination. Findings further support subcutaneous administration not affecting safety/efficacy profiles of trastuzumab in HER2-positive BC with increased flexibility in patient care. A fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection has recently been approved for the treatment of HER2-positive early/mBC, further addressing the increasing relevance of and need for patient-centric treatment strategies. Trial registration: NCT02402712

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10549-021-06145-3

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Patient dispositions. H SC subcutaneous trastuzumab, FUP follow-up period, P IV intravenous pertuzumab, PSP patient support program, PTAP post-trial access program, SoC standard of care
Fig. 1 Patient dispositions. H SC subcutaneous trastuzumab, FUP follow-up period, P IV intravenous pertuzumab, PSP patient support program, PTAP post-trial access program, SoC standard of careCC BY · PubMed Central
Fig. 2 Investigator-assessed PFS and OS. a, investigator-assessed PFS. b, OS. D IV intravenous docetaxel, H SC subcutaneous trastuzumab, NR not reported, OS overall survival, P IV intravenous pertuzumab, PFS progression-free survival
Fig. 2 Investigator-assessed PFS and OS. a, investigator-assessed PFS. b, OS. D IV intravenous docetaxel, H SC subcutaneous trastuzumab, NR not reported, OS overall survival, P IV intravenous pertuzumab, PFS progression-free survivalCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Research works printed but not linked: 1

  1. APM Health Europe (2020) Treating patients at home with subcutaneous injections of Roche’s Herceptin Hyclecta saves money [press review]. 31 January, 2020. https://www.apmhealtheurope.com/freestory/0/67360/treating-patients-at-home-with-subcutaneous-injections-of-roche-s-herceptin-hylecta-saves-money. Accessed November 2020

Cited by

See all 27

Metadata

Authors
Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., Cardona-Huerta, S., Monturus, E., Sequi, M., Restuccia, E., Benyunes, M., & Martín, M.
Affiliations
  • Ospedale Papa Giovanni XXIII (IT)
  • Velindre Cancer Centre (GB)
  • The Maria Sklodowska-Curie National Research Institute of Oncology (PL)
  • Central Clinical Hospital (PL)
  • National Institute of Oncology (HU)
  • Instituto Nacional de Cancerología (MX)
  • F. Hoffmann-La Roche AG (CH)
  • Genentech (US)
  • Universidad Complutense de Madrid (ES)
Venue
Breast Cancer Research and Treatment
Published
2021-03-21
Volume
187
Issue
2
Pages
467-476
ISSN
  • 0167-6806 (ISSN-L)
  • 1573-7217
OpenAlex
W3137191916
Cited by
22
References
27
Citations by year
2026: 3 · 2025: 3 · 2024: 6 · 2023: 4 · 2022: 3 · 2021: 3
FWCI
1.46
Type
journal article
Language
en
Open access
Licence
Locations
  • Breast Cancer Research and Treatment (publishedVersion, cc-by)
  • Research Square (acceptedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
F. Hoffmann-La Roche Ltd.
Topics
  • Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
  • Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
  • Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords
HER2-positive metastatic breast cancer, subcutaneous trastuzumab, pertuzumab, docetaxel, safety and tolerability, fixed-dose combination, progression-free survival, objective response rate, neutropenia, cardiac safety
MeSH terms
Trastuzumab, Docetaxel, Adolescent, Antineoplastic Combined Chemotherapy Protocols, Breast Neoplasms, Female, Humans, Stroke Volume, Biomarkers, Tumor, Ventricular Function, Left, Erb-b2 Receptor Tyrosine Kinases, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. https://app.cochat.ai/papers/10.1007/s10549-021-06145-3
The paper
Kuemmel, S., Tondini, C. A., Abraham, J., Nowecki, Z., Itrych, B., Hitre, E., Karaszewska, B., Juárez-Ramiro, A., Morales-Vásquez, F., Pérez-García, J. M., Cardona-Huerta, S., Monturus, E., Sequi, M., Restuccia, E., Benyunes, M., & Martín, M. (2021). Subcutaneous trastuzumab with pertuzumab and docetaxel in HER2-positive metastatic breast cancer: Final analysis of MetaPHER, a phase IIIb single-arm safety study. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-021-06145-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.